Food and Drug
Administration
Anti-Infective
Drugs Advisory Committee
September 12, 2006
Briefing Information
FDA
FDA Backgrounder (pdf)
FDA
Briefing Document Addendum and Errata from Division of Special
Pathogen and Transplant Products (pdf)
FDA
Briefing Document Addendum from Division of Drug Risk Evaluation
(pdf)
FDA Bibliography (pdf)
Oscient Pharmaceuticals Corporation
Disclaimer
The statements
contained in this document(s) are those of the product's sponsor,
not FDA, and FDA does not necessarily agree with the sponsor's
statements. FDA has not made a final determination about the
safety or effectiveness of the product described in this document.
Briefing Material
(pdf)
Errata (pdf)